Skip to main navigation Skip to search Skip to main content

Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study

  • KESTREL Investigators

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry

Nursing and Health Professions

Immunology and Microbiology

Pharmacology, Toxicology and Pharmaceutical Science

Neuroscience

Keyphrases